Track real-time stock market news and financial headlines across every major sector — from Biotech and Technology to Financials and Industrials. Every story on StockWire X comes with company context and sector classification so you can follow what matters to your portfolio.
Targeting Pancreatic Cancer and Beyond: Amplia Therapeutics (ASX:ATX)
Pancreatic cancer is one of the hardest cancers to treat, but Amplia Therapeutics (ASX:ATX | OTCQB:INNMF) may have found a way to help. Their drug, narmafotinib, works by breaking down the tough fibrous shield around tumours, letting chemotherapy do its job better.
Join this investor webinar to hear how the science is playing out in real trials, what the path to FDA approval looks like, and where the company is headed next, including new work in ovarian cancer and a promising new class of cancer drugs called kRAS inhibitors.
●Live investor Q&A
●Free to attend, no obligation
✓
You're registered!
Check your inbox for a confirmation email with the calendar invite.
Breaking ASX Alerts
Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
Breaking ASX announcements delivered within minutes
Alerts delivered with expert analysis
Optional text alert for subscribers
No spam policy, unsubscribe any time
Breaking ASX Alerts
Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
Breaking ASX announcements delivered within minutes
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.